drugset / Trial / NCT01002417
MCS in the Treatment of Lower Urinary Tract Symptoms
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Timeline
- Start
- 2010-07
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MCS-2 | Unknown | 15 mg | Oral |
| Comparator | MCS-2 | Unknown | 30 mg | Oral |